The Company announced that their therapeutics subsidiary has long viewed oral immune regulation as a promising platform and that they continue to pursue this platform through studies that involve treatment candidates of unmet medical needs. Enzo Biochem’s Vice President for Corporate Development, David Goldberg, mentioned that as they are growing their Life Sciences and Clinical Labs division they are also utlizing the experience and knowledge gained in drug discovery programs to better the position of Enzo Biochem in the rapidly growing companion diagnostics space.http://www.favstocks.com/enzo-biochem-th... further stated that the Company has made progress in the development of its drug screening platform that has yielded orally delivered small molecules having potential effects for bone disorders and diabetes.